2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. Post author:alarpharm Post published:21 . 4 . 2022 Post category:Media releases You Might Also Like 2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022 2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046 8 . 6 . 2021
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
